myNEO

Ottergemsesteenweg Zuid 808 B511

9000 Gent

BE

myNEO

Foundation date

01/12/2018

Sector

#Biotechnology / R&D Services

Subsector

Therapeutic areas

MyNEO is a Ghent-based biotech company that identifies, validates and explores therapeutic applications of personalized cancer vaccines starting from the patients tumor-specific mutations. The ImmunoEngine bioinformatic platform reports the personalized neoantigens of a patient sample, and is integrated within our end-to-end solution including state-of-the-art sequencing methods, in-vitro immunogenicity tests, and personalized mRNA vaccine construct production.

Upcoming events

Latest news

  • reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase

    Thursday October 21st 2021

  • Mithra announces Estelle® launch in Belgium

    Thursday October 21st 2021

  • Biotalys awarded multi-year grant to develop new biological solutions for cowpea and other legumes

    Wednesday October 20th 2021